Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 118

    2.

    HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system.

    Manos M, Frazier TW, Landgraf JM, Weiss M, Hodgkins P.

    Curr Med Res Opin. 2009 Dec;25(12):3001-10.

    PMID:
    19849639
    [PubMed - indexed for MEDLINE]
    3.

    Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion.

    Arnold LE, Bozzolo DR, Hodgkins P, McKay M, Beckett-Thurman L, Greenbaum M, Bukstein O, Patel A.

    Curr Med Res Opin. 2010 Jan;26(1):129-37.

    PMID:
    19916704
    [PubMed - indexed for MEDLINE]
    4.
    5.

    Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.

    Klassen AF, Miller A, Fine S.

    Pediatrics. 2004 Nov;114(5):e541-7.

    PMID:
    15520087
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

    Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group.

    Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

    PMID:
    14993578
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

    Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

    Pediatrics. 2001 Jun;107(6):E105.

    PMID:
    11389303
    [PubMed - indexed for MEDLINE]
    8.

    Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

    Clin Ther. 2007 Jun;29(6):1168-77.

    PMID:
    17692731
    [PubMed - indexed for MEDLINE]
    9.

    A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

    King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

    Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

    PMID:
    16796929
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.

    Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B.

    Curr Med Res Opin. 2011;27 Suppl 2:35-44. Epub 2011 Jul 25.

    PMID:
    21787126
    [PubMed - in process]
    11.

    Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

    Garnock-Jones KP, Keating GM.

    Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

    PMID:
    19445548
    [PubMed - indexed for MEDLINE]
    12.

    A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

    Rösler M, Fischer R, Ammer R, Ose C, Retz W.

    Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. Epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):368.

    PMID:
    19165529
    [PubMed - indexed for MEDLINE]
    14.

    [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

    Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

    Encephale. 2005 May-Jun;31(3):337-48. Review. French.

    PMID:
    16142049
    [PubMed - indexed for MEDLINE]
    16.

    Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.

    Efron D, Jarman F, Barker M.

    Pediatrics. 1997 Oct;100(4):662-6.

    PMID:
    9310521
    [PubMed - indexed for MEDLINE]
    17.

    Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.

    Anderson VR, Scott LJ.

    Drugs. 2006;66(8):1117-26. Review.

    PMID:
    16789796
    [PubMed - indexed for MEDLINE]
    18.

    Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.

    Yang P, Hsu HY, Chiou SS, Chao MC.

    Aust N Z J Psychiatry. 2007 Dec;41(12):998-1004.

    PMID:
    17999272
    [PubMed - indexed for MEDLINE]
    20.

    A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.

    Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD.

    J Clin Psychiatry. 2008 Jan;69(1):149-59. Erratum in: J Clin Psychiatry. 2008 Feb;69(2):329.

    PMID:
    18312050
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk